Bone Biologics (BBLG) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 01, 2023
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-40899
Entity Registrant Name	Bone Biologics Corporation
Entity Central Index Key	0001419554
Entity Tax Identification Number	42-1743430
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2 Burlington Woods Drive
Entity Address, Address Line Two	Ste 100
Entity Address, City or Town	Burlington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01803
City Area Code	(781)
Local Phone Number	552-4452
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		16,702,912
Common stock, $0.001 par value per share
Title of 12(b) Security	Common stock, $0.001 par value per share
Trading Symbol	BBLG
Security Exchange Name	NASDAQ
Warrants to Purchase Common stock, $0.001 par value per share
Title of 12(b) Security	Warrants to Purchase Common stock, $0.001 par value per share
Trading Symbol	BBLGW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current Assets
Cash	$ 6,188,319	$ 7,538,312
Prepaid expenses	595,434	956,925
Total assets	6,783,753	8,495,237
Current Liabilities
Accounts payable and accrued expenses	2,279,194	888,461
Warrant liability	1,732,160	1,659,468
Total current liabilities	4,011,354	2,547,929
Total liabilities	4,011,354	2,547,929
Commitments and Contingencies
Stockholders’ Equity
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at March 31, 2023 and December 31, 2022
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 16,702,912 and 15,301,986 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	16,701	15,300
Additional paid-in capital	78,425,824	77,892,235
Accumulated deficit	(75,670,126)	(71,960,227)
Total stockholders’ equity	2,772,399	5,947,308
Total liabilities and stockholders’ equity	$ 6,783,753	$ 8,495,237

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	16,702,912	15,301,986
Common stock, shares outstanding	16,702,912	15,301,986

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenues
Cost of revenues
Gross profit
Operating expenses
Research and development	2,590,645	36,400
General and administrative	556,892	653,099
Total operating expenses	3,147,537	689,499
Loss from operations	(3,147,537)	(689,499)
Other income (expenses)
Change in fair value of warrant liability	(562,918)
Interest income	556
Net loss	$ (3,709,899)	$ (689,499)
Weighted average shares outstanding - basic and diluted	16,115,577	10,350,579
Loss per share - basic and diluted	$ (0.23)	$ (0.07)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 10,350	$ 77,040,713	$ (70,475,607)	$ 6,575,456
Balance, shares at Dec. 31, 2021	10,350,574
Fair value of vested stock options issued to employees and directors		152,844		152,844
Net Loss			(689,499)	(689,499)
Share adjustment for October 2021 stock split rounding
Share adjustment for stock split rounding, shares	5
Balance at Mar. 31, 2022	$ 10,350	77,193,557	(71,165,106)	6,038,801
Balance, shares at Mar. 31, 2022	10,350,579
Balance at Dec. 31, 2022	$ 15,300	77,892,235	(71,960,227)	5,947,308
Balance, shares at Dec. 31, 2022	15,301,986
Fair value of vested stock options issued to employees and directors		44,764		44,764
Exercise of warrants	$ 1,401	(1,401)
Exercise of warrants, shares	1,400,926
Extinguishment of warrant liability upon exercise of warrants		490,226		490,226
Net Loss			(3,709,899)	(3,709,899)
Balance at Mar. 31, 2023	$ 16,701	$ 78,425,824	$ (75,670,126)	$ 2,772,399
Balance, shares at Mar. 31, 2023	16,702,912

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (3,709,899)	$ (689,499)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	44,764	152,844
Change in fair value of warrant liability	562,918
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	361,491	(279,128)
Accounts payable and accrued expenses	1,390,733	(44,996)
Net cash used in operating activities	(1,349,993)	(860,779)
Net decrease in cash	(1,349,993)	(860,779)
Cash, beginning of period	7,538,312	6,675,365
Cash, end of period	6,188,319	5,814,586
Supplemental information
Income taxes paid
Non-cash financing activities
Issuance of shares upon cashless exercise of warrants

The Company

The Company	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. The Company Bone Biologics Corporation (the “Company”) was incorporated under the laws of the State of Delaware on October 18, 2007 as AFH Acquisition X, Inc. Pursuant to a Merger Agreement, dated September 19, 2014, by and among the Company, its wholly-owned subsidiary, Bone Biologics Acquisition Corp., (“Merger Sub”), and Bone Biologics, Inc., Merger Sub merged with and into Bone Biologics Inc., with Bone Biologics Inc. remaining as the surviving corporation. On September 22, 2014, the Company changed its name to “Bone Biologics Corporation” and Bone Biologics, Inc. became a wholly owned subsidiary of the Company. Bone Biologics, Inc. was incorporated in California on September 9, 2004. We are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. The NELL-1 technology platform, has been licensed exclusively for worldwide applications to us through a technology transfer from the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). UCLA TDG and the Company received guidance from the FDA that NELL-1/DBM will be classified as a device/drug combination product with a pre-market approval filing (“PMA”). The production and marketing of the Company’s products and its ongoing research and development activities will be subject to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any combination product developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive regulatory approval process implemented by the FDA under the Food, Drug and Cosmetic Act. There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay or suspend clinical trials. The Company’s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and operate without infringing on the proprietary rights of others, both in the United States and other countries. There can be no assurance that patents issued to or licensed by the Company will not be challenged, invalidated, or circumvented, or that the rights granted thereunder will provide proprietary protection or competitive advantages to the Company. Going Concern The Company has no significant operating history and since inception to March 31, 2023 has incurred accumulated losses of approximately $ 75.7 9.8 3.7 million 1.3 million At March 31, 2023, we had cash of $ 6.2 . Available cash is expected to fund up to commencement of our pilot clinical study. We anticipate that it will require approximately $ 15 27 The Company will continue to attempt to raise additional debt and/or equity financing to fund future operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet the Company’s needs. If cash resources are insufficient to satisfy the Company’s on-going cash requirements, the Company will be required to scale back or discontinue its product development programs, or obtain funds if available (although there can be no certainties) through strategic alliances that may require the Company to relinquish rights to its technology, substantially reduce or discontinue its operations entirely. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The interim condensed consolidated financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under the accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes that the disclosures are adequate to make the information presented not misleading. The condensed consolidated balance sheet information as of December 31, 2022 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the SEC on March 30, 2023 (the “2022 Annual Report”). These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2022 and notes thereto included in the 2022 Annual Report. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the entire fiscal year ended December 31, 2023 or for any other period. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the accrual for potential liabilities, the valuation of debt and equity instruments, the valuation of stock options and warrants issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates. Impact of the Novel Coronavirus (COVID-19) on the Company’s Business Operations The global outbreak of the novel coronavirus (COVID-19) has led to severe disruptions in general economic activities worldwide, as businesses and governments have taken broad actions to mitigate this public health crisis. In light of the uncertain and continually evolving situation relating to the spread of COVID-19, this pandemic could pose a risk to the Company. The extent to which the coronavirus may impact the Company’s business operations will depend on future developments, which are highly uncertain and cannot be predicted at this time. The Company intends to continue to monitor the situation and may adjust its current business plans as more information and guidance become available. The coronavirus pandemic presents a challenge to medical facilities worldwide. As the Company’s clinical trials are conducted on an outpatient basis, it is not currently possible to predict the full impact of this developing health crisis on such clinical trials, which could include delays in and increased costs of such clinical trials. Current indications from the clinical research organizations conducting the clinical trials for the Company are that such clinical trials are being delayed or extended for several months as a result of the coronavirus pandemic. There is also significant uncertainty as to the effect that the coronavirus may have on the amount and type of financing available to the Company in the future. Inflation Macroeconomic factors such as inflation, rising interest rates, governmental responses there to and possible recession caused thereby also add significant uncertainty to our operations and possible effects to the amount and type of financing available to the Company in the future. Cash Cash primarily consists of bank demand deposits maintained by a major financial institution. The Company’s policy is to maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the “FDIC”) and/or by the Securities Investor Protection Corporation (the “SIPC”). The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $ 250,000 500,000 While the Company and its bank has not been directly affected by the recent failures of certain banks, the banking industry overall has experienced disruption and uncertainty, which could put additional pressures on the Company’s bank and other banks, and may negatively impact the availability and costs for various banking and investment offerings. The failure of a bank, or other adverse conditions in the financial or credit markets impacting financial institutions at which we maintain balances, could adversely impact our liquidity and financial performance. There can be no assurance that our deposits in excess of the FDIC or other comparable insurance limits will be backstopped by the U.S., or that any bank or financial institution with which we do business will be able to obtain needed liquidity from other banks, government institutions or by acquisition in the event of a failure or liquidity crisis. Fair Value of Financial Instruments Accounting standards require certain assets and liabilities be reported at fair value in the financial statements and provide a framework for establishing that fair value. The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from embedded derivatives associated with certain warrants to purchase common stock. The fair value of financial instruments measured on a recurring basis was as follows as of March 31, 2023: Schedule of Fair Value Liabilities Measured On Recurring Basis As of March 31, 2023 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 1,732,160 — — $ 1,732,160 Total liabilities at fair value $ 1,732,160 — — $ 1,732,160 The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis using unobservable level 3 inputs for the three period ended March 31, 2023 as follows: Schedule of Warrant Liability Measured Fair Value on a Recurring Basis Using Unobservable March 31, 2023 Warrant liability Balance as of beginning of period – December 31, 2022 $ 1,659,468 Extinguishment of warrant liability upon exercise of warrants (490,226 ) Change in fair value 562,918 Balance as of March 31, 2023 $ 1,732,160 The Company believes the carrying amount of certain financial instruments, including cash and accounts payable approximate their values based on their short-term nature and are excluded from the fair value tables above. Prepaid Expenses At March 31, 2023, prepaid expenses consist of prepaid insurance and prepaid services. Prepaid expenses are amounts paid to secure the use of assets or the receipt of services at a future date or continuously over one or more future periods. When the prepaid expenses are eventually consumed, they are charged to expense. The Company had $ 595,434 956,925 Stock Based Compensation ASC 718, Compensation – Stock Compensation Loss per Common Share Basic loss per share is computed by dividing the loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if options and warrants were to be exercised or converted or otherwise resulted in the issuance of common stock that then shared in the earnings of the entity. Since the effects of outstanding options and warrants are anti-dilutive for the three months ended March 31, 2023 and 2022, shares of common stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of March 31, 2023 and 2022: Schedule of Anti dilutive Securities Excluded from Computation of Earnings Per Share March 31, 2023 2022 Warrants 12,443,428 1,827,650 Stock options 509,454 342,294 Anti dilutive Securities 12,952,882 2,169,944 New Accounting Standards In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40).” ASU 2020-06 reduces the number of accounting models for convertible debt instruments by eliminating the cash conversion and beneficial conversion models. The diluted net income per share calculation for convertible instruments will require the Company to use the if-converted method. For contracts in an entity’s own equity, the type of contracts primarily affected by this update are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement conditions of the derivative scope exception. This update simplifies the related settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective January 1, 2024, for the Company and the provisions of this update can be adopted using either the modified retrospective method or a fully retrospective method. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Effective January 1, 2021, the Company early adopted ASU 2020-06 and that adoption did not have an impact on our financial statements and related disclosures. Other recent accounting pronouncements and guidance issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Warrant Liability

Warrant Liability	3 Months Ended
	Mar. 31, 2023
Warrant Liability
Warrant Liability	3. Warrant Liability In October 2022, the Company completed a public equity offering, which included the issuance of 13,001,445 The warrant liability was valued at the following dates using a Black-Scholes model with the following assumptions: Schedule of Warrant Liability Black-Scholes Model March 31, 2023 December 31, 2022 Warrant liability: Risk-free interest rate 3.67 % 4.26 % Expected volatility 115.06 % 112.58 % Expected life (in years) 4.54 4.78 Expected dividend yield - - Fair Value: Warrant liability $ 1,732,160 $ 1,659,468 The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. Expected volatility was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The expected term of the warrants granted are determined based on the duration of time the warrants are expected to be outstanding. The dividend yield on the Company’s warrants is assumed to be zero as the Company has not historically paid dividends.

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders’ Equity	4. Stockholders’ Equity Preferred Stock The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 20,000,000 No Common Stock The Company’s amended and restated certificate of incorporation authorizes the Company to issue a total of 100,000,000 16,702,912 15,301,986 In February 2023, 1,400,926 1,400,926

Common Stock Warrants

Common Stock Warrants	3 Months Ended
	Mar. 31, 2023
Common Stock Warrants
Common Stock Warrants	5. Common Stock Warrants A summary of warrant activity for the three months ended March 31, 2023 is presented below: Schedule of Warrant Activity Subject to Exercise Number of Weighted Weighted Outstanding as of December 31, 2022 13,844,354 $ 1.78 4.65 Granted – 2023 - - - Forfeited/Expired – 2023 - - - Exercised – 2023 (1,400,926 ) 4.54 4.78 Outstanding as of March 31, 2023 12,443,428 $ 1.98 4.39 As of March 31, 2023, the Company had outstanding vested and unexercised Common Stock Warrants as follows: Schedule of Outstanding Vested and Unexercised Common Stock Warrants Date Issued Exercise Price Number of Expiration date October 2021 $ 6.30 1,827,650 October 13, 2026 October 2022 $ 1.62 4,522,703 October 12, 2027 October 2022 $ 1.35 4,333,815 October 12, 2027 October 2022 $ 0.00 1,759,260 October 12, 2027 Total outstanding warrants at March 31, 2023 12,443,428 Based on a fair market value of $ 0.26 1,759,260 454,769

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	6. Stock-based Compensation 2015 Equity Incentive Plan The Company has 1,077,529 5 Awards may be granted under our 2015 Equity Incentive Plan to our employees, including officers, director or consultants, and our present or future affiliated entities. While we may grant incentive stock options only to employees, we may grant non-statutory stock options, stock appreciation rights, restricted stock purchase rights or bonuses, restricted stock units, performance shares, performance units and cash-based awards or other stock based awards to any eligible participant. The 2015 Equity Incentive Plan is administered by our compensation committee. Subject to the provisions of our 2015 Equity Incentive Plan, the compensation committee determines, in its discretion, the persons to whom, and the times at which, awards are granted, as well as the size, terms and conditions of each award. All awards are evidenced by a written agreement between us and the holder of the award. The compensation committee has the authority to construe and interpret the terms of our 2015 Equity Incentive Plan and awards granted under our 2015 Equity Incentive Plan. A summary of stock option activity for the three months ended March 31, 2023 is presented below: Schedule of Stock Option Activity Subject to Exercise Number of Weighted Average Weighted Aggregate Outstanding as of December 31, 2022 452,829 $ 16.84 5.60 $ - Granted – 2023 56,625 0.24 2.00 - Forfeited/Expired – 2023 - - - - Exercised – 2023 - - - - Outstanding as of March 31, 2023 509,454 $ 15.00 4.82 $ 1,048 Options vested and exercisable at March 31, 2023 481,821 $ 15.76 4.55 $ 1,048 As of March 31, 2023, the Company had outstanding stock options as follows: Schedule of Outstanding Stock Options Date Issued Exercise Price Number of Expiration date August 2015 $ 39.75 41,624 December 27, 2025 September 2015 $ 39.75 8,000 December 27, 2025 November 2015 $ 39.75 48,986 December 27, 2025 December 2015 $ 39.75 2,228 December 27, 2025 January 2016 $ 39.75 51,032 January 9, 2026 May 2016 $ 51.25 10,766 May 26, 2026 September 2016 $ 51.25 3,973 May 31, 2026 January 2017 $ 51.25 2,142 January 1, 2027 January 2018 $ 49.25 1,566 January 1, 2028 January 2019 $ 2.35 21,964 January 1, 2029 October 2021 $ 5.25 48,847 October 26, 2031 January 2022 $ 3.52 26,166 January 1, 2032 January 2022 $ 3.72 50,000 January 1, 2024 January 2022 $ 3.72 25,000 January 3, 2024 August 2022 $ 1.61 110,535 August 23, 2032 January 2023 $ 0.24 56,625 January 25, 2025 Total outstanding options at March 31, 2023 509,454 Based on a fair value of $ 0.26 56,625 1,048 There were 56,625 11,948 44,764 152,844 The Company utilized the Black-Scholes option-pricing model. The assumptions used for the three months ended March 31, 2023 are as follows: Schedule of Assumptions Using Black-Scholes Option Pricing Model March 31, Risk free interest rate 4.67 % Expected life (in years) 1 Expected Volatility 136.03 % Expected dividend yield 0 % At March 31, 2023, management determined that the Company has limited trading history by which to determine the volatility of its own common stock price. Accordingly, the fair value of the options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method. The expected life of the options used was based on the contractual life of the option granted. Stock-based compensation is a non-cash expense because we settle these obligations by issuing shares of our common stock from our authorized shares instead of settling such obligations with cash payments. As of March 31, 2023, total unrecognized compensation cost related to unvested stock options was $ 22,140 0.25

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies UCLA TDG Exclusive License Agreement Effective April 9, 2019, we entered into an Amended and Restated Exclusive License Agreement dated as of March 21, 2019 and amended through three sets of amendments (as so amended the “Amended License Agreement”) with the UCLA TDG. The Amended License Agreement amends and restates the Amended and Restated Exclusive License Agreement, dated as of June 19, 2017 (the “2017 Agreement”). The 2017 Agreement amended and restated the Exclusive License Agreement, effective March 15, 2006, between the Company and UCLA TDG, as amended by ten amendments. Under the terms of the Amended License Agreement, the Regents have continued to grant us exclusive rights to develop and commercialize NELL-1 (the “Licensed Product”) for spinal fusion by local administration, osteoporosis and trauma applications. The Licensed Product is a recombinant human protein growth factor that is essential for normal bone development. We have agreed to pay an annual maintenance fee to UCLA TDG of $ 10,000 50,000 250,000 0.333 10 20 We are obligated to make the following milestone payments to UCLA TDG for each Licensed Product or Licensed Method: ● $ 100,000 ● $ 250,000 ● $ 500,000 ● $ 1,000,000 We are also obligated pay to UCLA TDG a fee (the “Diligence Fee”) of $ 8,000,000 ● Due upon cumulative Net Sales equaling $50,000,000 following the Triggering Sale Date - $2,000,000; ● Due upon cumulative Net Sales equaling $100,000,000 following the Triggering Sale Date - $2,000,000; ● Due upon cumulative Net Sales equaling $200,000,000 following the Triggering Sale Date - $4,000,000 Our obligation to pay the Diligence Fee will survive termination or expiration of the agreement and we are prohibited from assigning, selling, or otherwise transferring any of its assets related to any Licensed Product unless our Diligence Fee obligation is assigned, sold, or transferred along with such assets, or unless we pay UCLA TDG the Diligence Fee within ten (10) days of such assignment, sale or other transfer of such rights to any Licensed Product. We are also obligated to pay UCLA TDG a cash milestone payment within thirty (30) days of a Liquidity Event (including a Change of Control Transaction and a payment election by UCLA TDG exercisable after December 22, 2016) such payment to equal the greater of: ● $ 500,000 ● 2 As of March 31, 2023, none of the above milestones has been met. We are obligated to diligently proceed with developing and commercializing licensed products under UCLA TDG patents set forth in the Amended License Agreement. UCLA TDG has the right to either terminate the license or reduce the license to a non-exclusive license if we do not meet certain diligence milestone deadlines set forth in the Amended License Agreement. We must reimburse or pre-pay UCLA TDG for patent prosecution and maintenance costs incurred during the term of the Amended License Agreement. We have the right to bring infringement actions against third party infringers of the Amended License Agreement, UCLA TDG may join voluntarily, at its own expense, or, at our expense, be joined involuntarily to the action. We are required to indemnify UCLA TDG against any third party claims arising out of our exercise of the rights under the Amended License Agreement or any sublicense. Payments to UCLA TDG under the Amended License Agreement for the three months ended March 31, 2023 and 2022 were $ 16,606 22,149 Development Contracts The Company has two contracts with one vendor for development activities of NELL-1. As of March 31, 2023, there was $ 28,200 2,132,791 3,648,991 At March 31, 2021 there exists a concentration of payables to one vendor of approximately 96% Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company’s management does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows. In July 2019, Dr. Bessie (Chia) Soo and Dr. Kang (Eric) Ting (“Plaintiffs”) filed a complaint (the “Complaint”) in federal court in Massachusetts against the Company, Bruce Stroever (“Stroever”), John Booth (“Booth”), Stephen LaNeve (“LaNeve”, and together with Stroever and Booth, the “Individual Defendants”), and MTF Biologics (f/k/a The Musculoskeletal Transplant Foundation, Inc.) (“MTF”). The Complaint alleges claims for breach of contract against the Company and tortious interference with contract against the Individual Defendants and MTF arising from the termination of the Professional Service Agreements, dated as of January 8, 2016, between the Company and each of the Plaintiffs. The Individual Defendants have been sued for actions taken by them in connection with their service to the Company as directors and/or officers of the Company. As such, the Company has certain indemnification obligations to the Individual Defendants. The Company and the Individual Defendants intend to vigorously defend against the allegations in the Complaint. Although the Complaint was filed several years ago, due to the Covid-19 Pandemic and long delays in the court ruling on various motions to dismiss, in terms of case progression the case is still in its early stages with the claims in the case not being set until April 2022 and preliminary discovery starting since then. Based on the early stage of the litigation, it is not possible to estimate the amount or range of any possible loss arising from the expenditure of defense fees, a judgment or settlement of the matter. NASDAQ Notice On November 17, 2022, the Company received a written notice from the NASDAQ Stock Market LLC (“Nasdaq”) that the Company has not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for a period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price of $ 1.00 In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided a compliance period of 180 calendar days from the date of the Notice, or until May 16, 2023, to regain compliance with the minimum closing bid price requirement. If the Company does not regain compliance during the compliance period ending May 16, 2023, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify for the second compliance period, the Company must (i) meet the continued listing requirement for market value of publicly-held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum closing bid price requirement and (ii) notify Nasdaq of its intent to cure the deficiency. As of March 31, 2023, the Company did not meet the initial listing standard for stockholders’ equity applicable for the second compliance period. Accordingly, the Company expects that it will receive a notice that the Company’s securities will be subject to delisting. If such notice is received, the Company plans to appeal the delisting determination to the Nasdaq Listing Qualifications Panel. The Company can achieve compliance with the minimum closing bid price requirement if, during the appeal process, the minimum closing bid price per share of the Company’s common stock is at least $ 1.00 In connection with regaining compliance, on May 1, 2023, the Company received the approval of the requisite number of holders of the shares of our common stock to amend our certificate of incorporation to effect a reverse split of the shares of our common stock at a ratio of 1-for-20 to 1-for-50

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	8. Subsequent Events On May 1, 2023, the Company received the approval of the requisite number of holders of the shares of our common stock to amend our certificate of incorporation to effect a reverse split of the shares of our common stock at a ratio of 1-for-20 to 1-for-50

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The interim condensed consolidated financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under the accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company believes that the disclosures are adequate to make the information presented not misleading. The condensed consolidated balance sheet information as of December 31, 2022 was derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K filed with the SEC on March 30, 2023 (the “2022 Annual Report”). These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2022 and notes thereto included in the 2022 Annual Report. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the entire fiscal year ended December 31, 2023 or for any other period.
Use of Estimates	Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the accrual for potential liabilities, the valuation of debt and equity instruments, the valuation of stock options and warrants issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates.
Impact of the Novel Coronavirus (COVID-19) on the Company’s Business Operations	Impact of the Novel Coronavirus (COVID-19) on the Company’s Business Operations The global outbreak of the novel coronavirus (COVID-19) has led to severe disruptions in general economic activities worldwide, as businesses and governments have taken broad actions to mitigate this public health crisis. In light of the uncertain and continually evolving situation relating to the spread of COVID-19, this pandemic could pose a risk to the Company. The extent to which the coronavirus may impact the Company’s business operations will depend on future developments, which are highly uncertain and cannot be predicted at this time. The Company intends to continue to monitor the situation and may adjust its current business plans as more information and guidance become available. The coronavirus pandemic presents a challenge to medical facilities worldwide. As the Company’s clinical trials are conducted on an outpatient basis, it is not currently possible to predict the full impact of this developing health crisis on such clinical trials, which could include delays in and increased costs of such clinical trials. Current indications from the clinical research organizations conducting the clinical trials for the Company are that such clinical trials are being delayed or extended for several months as a result of the coronavirus pandemic. There is also significant uncertainty as to the effect that the coronavirus may have on the amount and type of financing available to the Company in the future.
Inflation	Inflation Macroeconomic factors such as inflation, rising interest rates, governmental responses there to and possible recession caused thereby also add significant uncertainty to our operations and possible effects to the amount and type of financing available to the Company in the future.
Cash	Cash Cash primarily consists of bank demand deposits maintained by a major financial institution. The Company’s policy is to maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the “FDIC”) and/or by the Securities Investor Protection Corporation (the “SIPC”). The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $ 250,000 500,000 While the Company and its bank has not been directly affected by the recent failures of certain banks, the banking industry overall has experienced disruption and uncertainty, which could put additional pressures on the Company’s bank and other banks, and may negatively impact the availability and costs for various banking and investment offerings. The failure of a bank, or other adverse conditions in the financial or credit markets impacting financial institutions at which we maintain balances, could adversely impact our liquidity and financial performance. There can be no assurance that our deposits in excess of the FDIC or other comparable insurance limits will be backstopped by the U.S., or that any bank or financial institution with which we do business will be able to obtain needed liquidity from other banks, government institutions or by acquisition in the event of a failure or liquidity crisis.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting standards require certain assets and liabilities be reported at fair value in the financial statements and provide a framework for establishing that fair value. The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from embedded derivatives associated with certain warrants to purchase common stock. The fair value of financial instruments measured on a recurring basis was as follows as of March 31, 2023: Schedule of Fair Value Liabilities Measured On Recurring Basis As of March 31, 2023 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 1,732,160 — — $ 1,732,160 Total liabilities at fair value $ 1,732,160 — — $ 1,732,160 The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis using unobservable level 3 inputs for the three period ended March 31, 2023 as follows: Schedule of Warrant Liability Measured Fair Value on a Recurring Basis Using Unobservable March 31, 2023 Warrant liability Balance as of beginning of period – December 31, 2022 $ 1,659,468 Extinguishment of warrant liability upon exercise of warrants (490,226 ) Change in fair value 562,918 Balance as of March 31, 2023 $ 1,732,160 The Company believes the carrying amount of certain financial instruments, including cash and accounts payable approximate their values based on their short-term nature and are excluded from the fair value tables above.
Prepaid Expenses	Prepaid Expenses At March 31, 2023, prepaid expenses consist of prepaid insurance and prepaid services. Prepaid expenses are amounts paid to secure the use of assets or the receipt of services at a future date or continuously over one or more future periods. When the prepaid expenses are eventually consumed, they are charged to expense. The Company had $ 595,434 956,925
Stock Based Compensation	Stock Based Compensation ASC 718, Compensation – Stock Compensation
Loss per Common Share	Loss per Common Share Basic loss per share is computed by dividing the loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if options and warrants were to be exercised or converted or otherwise resulted in the issuance of common stock that then shared in the earnings of the entity. Since the effects of outstanding options and warrants are anti-dilutive for the three months ended March 31, 2023 and 2022, shares of common stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of March 31, 2023 and 2022: Schedule of Anti dilutive Securities Excluded from Computation of Earnings Per Share March 31, 2023 2022 Warrants 12,443,428 1,827,650 Stock options 509,454 342,294 Anti dilutive Securities 12,952,882 2,169,944
New Accounting Standards	New Accounting Standards In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40).” ASU 2020-06 reduces the number of accounting models for convertible debt instruments by eliminating the cash conversion and beneficial conversion models. The diluted net income per share calculation for convertible instruments will require the Company to use the if-converted method. For contracts in an entity’s own equity, the type of contracts primarily affected by this update are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement conditions of the derivative scope exception. This update simplifies the related settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective January 1, 2024, for the Company and the provisions of this update can be adopted using either the modified retrospective method or a fully retrospective method. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Effective January 1, 2021, the Company early adopted ASU 2020-06 and that adoption did not have an impact on our financial statements and related disclosures. Other recent accounting pronouncements and guidance issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Fair Value Liabilities Measured On Recurring Basis	The fair value of financial instruments measured on a recurring basis was as follows as of March 31, 2023: Schedule of Fair Value Liabilities Measured On Recurring Basis As of March 31, 2023 Description Total Level 1 Level 2 Level 3 Liabilities: Warrant liability $ 1,732,160 — — $ 1,732,160 Total liabilities at fair value $ 1,732,160 — — $ 1,732,160
Schedule of Warrant Liability Measured Fair Value on a Recurring Basis Using Unobservable	The following table provides a roll-forward of the warrant liability measured at fair value on a recurring basis using unobservable level 3 inputs for the three period ended March 31, 2023 as follows: Schedule of Warrant Liability Measured Fair Value on a Recurring Basis Using Unobservable March 31, 2023 Warrant liability Balance as of beginning of period – December 31, 2022 $ 1,659,468 Extinguishment of warrant liability upon exercise of warrants (490,226 ) Change in fair value 562,918 Balance as of March 31, 2023 $ 1,732,160
Schedule of Anti dilutive Securities Excluded from Computation of Earnings Per Share	The following sets forth the number of shares of common stock underlying outstanding options, warrants, and convertible debt as of March 31, 2023 and 2022: Schedule of Anti dilutive Securities Excluded from Computation of Earnings Per Share March 31, 2023 2022 Warrants 12,443,428 1,827,650 Stock options 509,454 342,294 Anti dilutive Securities 12,952,882 2,169,944

Warrant Liability (Tables)

Warrant Liability (Tables)	3 Months Ended
	Mar. 31, 2023
Warrant Liability
Schedule of Warrant Liability Black-Scholes Model	The warrant liability was valued at the following dates using a Black-Scholes model with the following assumptions: Schedule of Warrant Liability Black-Scholes Model March 31, 2023 December 31, 2022 Warrant liability: Risk-free interest rate 3.67 % 4.26 % Expected volatility 115.06 % 112.58 % Expected life (in years) 4.54 4.78 Expected dividend yield - - Fair Value: Warrant liability $ 1,732,160 $ 1,659,468

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	3 Months Ended
	Mar. 31, 2023
Common Stock Warrants
Schedule of Warrant Activity	A summary of warrant activity for the three months ended March 31, 2023 is presented below: Schedule of Warrant Activity Subject to Exercise Number of Weighted Weighted Outstanding as of December 31, 2022 13,844,354 $ 1.78 4.65 Granted – 2023 - - - Forfeited/Expired – 2023 - - - Exercised – 2023 (1,400,926 ) 4.54 4.78 Outstanding as of March 31, 2023 12,443,428 $ 1.98 4.39
Schedule of Outstanding Vested and Unexercised Common Stock Warrants	As of March 31, 2023, the Company had outstanding vested and unexercised Common Stock Warrants as follows: Schedule of Outstanding Vested and Unexercised Common Stock Warrants Date Issued Exercise Price Number of Expiration date October 2021 $ 6.30 1,827,650 October 13, 2026 October 2022 $ 1.62 4,522,703 October 12, 2027 October 2022 $ 1.35 4,333,815 October 12, 2027 October 2022 $ 0.00 1,759,260 October 12, 2027 Total outstanding warrants at March 31, 2023 12,443,428

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	A summary of stock option activity for the three months ended March 31, 2023 is presented below: Schedule of Stock Option Activity Subject to Exercise Number of Weighted Average Weighted Aggregate Outstanding as of December 31, 2022 452,829 $ 16.84 5.60 $ - Granted – 2023 56,625 0.24 2.00 - Forfeited/Expired – 2023 - - - - Exercised – 2023 - - - - Outstanding as of March 31, 2023 509,454 $ 15.00 4.82 $ 1,048 Options vested and exercisable at March 31, 2023 481,821 $ 15.76 4.55 $ 1,048
Schedule of Outstanding Stock Options	As of March 31, 2023, the Company had outstanding stock options as follows: Schedule of Outstanding Stock Options Date Issued Exercise Price Number of Expiration date August 2015 $ 39.75 41,624 December 27, 2025 September 2015 $ 39.75 8,000 December 27, 2025 November 2015 $ 39.75 48,986 December 27, 2025 December 2015 $ 39.75 2,228 December 27, 2025 January 2016 $ 39.75 51,032 January 9, 2026 May 2016 $ 51.25 10,766 May 26, 2026 September 2016 $ 51.25 3,973 May 31, 2026 January 2017 $ 51.25 2,142 January 1, 2027 January 2018 $ 49.25 1,566 January 1, 2028 January 2019 $ 2.35 21,964 January 1, 2029 October 2021 $ 5.25 48,847 October 26, 2031 January 2022 $ 3.52 26,166 January 1, 2032 January 2022 $ 3.72 50,000 January 1, 2024 January 2022 $ 3.72 25,000 January 3, 2024 August 2022 $ 1.61 110,535 August 23, 2032 January 2023 $ 0.24 56,625 January 25, 2025 Total outstanding options at March 31, 2023 509,454
Schedule of Assumptions Using Black-Scholes Option Pricing Model	The Company utilized the Black-Scholes option-pricing model. The assumptions used for the three months ended March 31, 2023 are as follows: Schedule of Assumptions Using Black-Scholes Option Pricing Model March 31, Risk free interest rate 4.67 % Expected life (in years) 1 Expected Volatility 136.03 % Expected dividend yield 0 %

The Company (Details Narrative)

The Company (Details Narrative) - USD ($)		3 Months Ended
	Oct. 12, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Accumulated deficit		$ 75,670,126		$ 71,960,227
Operating expenses		9,800,000
Net loss		3,709,899	$ 689,499
Net cash used in operating activities		1,349,993	$ 860,779
Cash		$ 6,200,000
Sale of stock, consideration received on transaction	$ 15,000,000
FDA Spine Interbody Fusion [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Sale of stock, consideration received on transaction	$ 27,000,000

Schedule of Fair Value Liabilit

Schedule of Fair Value Liabilities Measured On Recurring Basis (Details) - Fair Value, Recurring [Member]	Mar. 31, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 1,732,160
Total liabilities at fair value	1,732,160
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability
Total liabilities at fair value
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability
Total liabilities at fair value
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	1,732,160
Total liabilities at fair value	$ 1,732,160

Schedule of Warrant Liability M

Schedule of Warrant Liability Measured Fair Value on a Recurring Basis Using Unobservable (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Accounting Policies [Abstract]
Balance as of beginning of period – December 31, 2022	$ 1,659,468
Extinguishment of warrant liability upon exercise of warrants	(490,226)
Change in fair value including accrued interest	562,918
Balance as of March 31, 2023	$ 1,732,160

Schedule of Anti dilutive Secur

Schedule of Anti dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive Securities	12,952,882	2,169,944
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive Securities	12,443,428	1,827,650
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive Securities	509,454	342,294

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Cash FDIC insured amount	$ 250,000
Cash SIPC insured amount	500,000
Prepaid expenses	$ 595,434	$ 956,925

Schedule of Warrant Liability B

Schedule of Warrant Liability Black-Scholes Model (Details)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability	$ 1,732,160	$ 1,659,468
Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability	$ 1,732,160	$ 1,659,468
Measurement Input, Risk Free Interest Rate [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.0367	0.0426
Measurement Input Expected Volatility [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	1.1506	1.1258
Measurement Input, Expected Term [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	4.54	4.78
Measurement Input Expected Dividend Yield [Member] | Warrant [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input

Warrant Liability (Details Narr

Warrant Liability (Details Narrative)	1 Months Ended
	Oct. 31, 2022 shares
Warrant Liability
Issuance of warrant shares	13,001,445

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - shares	1 Months Ended
	Feb. 28, 2023	Mar. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Preferred stock, shares authorized		20,000,000	20,000,000
Preferred stock, shares issued		0	0
Common stock, shares authorized		100,000,000	100,000,000
Common stock, shares outstanding		16,702,912	15,301,986
Series C Warrant [Member]
Class of Stock [Line Items]
Warrant exchange for common stock	1,400,926
Series C Warrant [Member] | Common Stock [Member]
Class of Stock [Line Items]
Warrant exchange for common stock	1,400,926

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2023 shares
Common Stock Warrants
Number of Warrants, Outstanding	13,844,354
Weighted Average Exercise Price, Outstanding	1.78
Weighted Average Life (Years), Outstanding	4 years 7 months 24 days
Number of Warrants,Granted
Weighted Average Exercise Price, Granted
Number of Warrants, Forfeited/Expired
Weighted Average Exercise Price ,Forfeited/Expired
Number of Warrants, Exercised	(1,400,926)
Weighted Average Exercise Price, Exercised	4.54
Weighted Average Life (Years), Exercised	4 years 9 months 10 days
Number of Warrants, Outstanding	12,443,428
Weighted Average Exercise Price, Outstanding	1.98
Weighted Average Life (Years), Outstanding	4 years 4 months 20 days

Schedule of Outstanding Vested

Schedule of Outstanding Vested and Unexercised Common Stock Warrants (Details) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Warrants	12,443,428	13,844,354
October 2021 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	$ 6.30
Number of Warrants	1,827,650
ExpirationDate	Oct. 13, 2026
October 2022 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	$ 1.62
Number of Warrants	4,522,703
ExpirationDate	Oct. 12, 2027
October 2022 1 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	$ 1.35
Number of Warrants	4,333,815
ExpirationDate	Oct. 12, 2027
October 2022 2 [Member] | Vested and Unexercised Common Stock Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	$ 0
Number of Warrants	1,759,260
ExpirationDate	Oct. 12, 2027

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative) - USD ($)	Mar. 31, 2023	Nov. 17, 2022
Common Stock Warrants
Fair market value	$ 0.26	$ 1
Exercisable unexercised, shares	1,759,260
Exercisable unexercised, intrinsic value	$ 454,769

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of Options Outstanding, Beginning balance | shares	452,829
Weighted Average Exercise Price, Outstanding, Beginning balance | $ / shares	$ 16.84
Weighted Average Life (Years), Outstanding	5 years 7 months 6 days
Aggregate Intrinsic Value, Outstanding, Beginning balance | $
Number of Options, Granted | shares	56,625
Weighted Average Exercise Price, Granted | $ / shares	$ 0.24
Weighted Average Life (Years), Granted	2 years
Number of Options, Forfeited/Expired | shares
Weighted Average Exercise Price, Forfeited/Expired | $ / shares
Number of Options, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Number of Options Outstanding, Ending balance | shares	509,454
Weighted Average Exercise Price, Outstanding, Ending balance | $ / shares	$ 15
Weighted Average Life (Years), Outstanding	4 years 9 months 25 days
Aggregate Intrinsic Value, Outstanding, Ending balance | $	$ 1,048
Number of Options Exercisable, Ending balance | shares	481,821
Weighted Average Exercise Price, Exercisable, Ending balance | $ / shares	$ 15.76
Weighted Average Exercise Price, Exercisable, Year	4 years 6 months 18 days
Aggregate Intrinsic Value, Outstanding, Options vested and exercisable, Ending balance | $	$ 1,048

Schedule of Outstanding Stock O

Schedule of Outstanding Stock Options (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options	509,454
August 2015 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 39.75
Number of options	41,624
Expiration date	Dec. 27, 2025
September 2015 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 39.75
Number of options	8,000
Expiration date	Dec. 27, 2025
November 2015 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 39.75
Number of options	48,986
Expiration date	Dec. 27, 2025
December 2015 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 39.75
Number of options	2,228
Expiration date	Dec. 27, 2025
January 2016 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 39.75
Number of options	51,032
Expiration date	Jan. 09, 2026
May 2016 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 51.25
Number of options	10,766
Expiration date	May 26, 2026
September 2016 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 51.25
Number of options	3,973
Expiration date	May 31, 2026
January 2017 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 51.25
Number of options	2,142
Expiration date	Jan. 01, 2027
January 2018 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 49.25
Number of options	1,566
Expiration date	Jan. 01, 2028
January 2019 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 2.35
Number of options	21,964
Expiration date	Jan. 01, 2029
October 2021 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 5.25
Number of options	48,847
Expiration date	Oct. 26, 2031
January 2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 3.52
Number of options	26,166
Expiration date	Jan. 01, 2032
January 2022 1 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 3.72
Number of options	50,000
Expiration date	Jan. 01, 2024
January 2022 2 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 3.72
Number of options	25,000
Expiration date	Jan. 03, 2024
August 2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.61
Number of options	110,535
Expiration date	Aug. 23, 2032
January Two Thousand Twenty Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.24
Number of options	56,625
Expiration date	Jan. 25, 2025

Schedule of Assumptions Using B

Schedule of Assumptions Using Black-Scholes Option Pricing Model (Details)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Risk free interest rate	4.67%
Expected life (in years)	1 year
Expected Volatility	136.03%
Expected dividend yield	0%

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Nov. 17, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value	$ 0.26		$ 1
Options granted	56,625
Exercisable but unexercised common stock warrants	$ 1,048
Fair value of stock option	11,948
Share based compensation expense	$ 44,764	$ 152,844
Weighted average life (Years), Outstanding	5 years 7 months 6 days
2015 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	1,077,529
Percentage of stock issued and outstanding	5%
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation cost	$ 22,140
Weighted average life (Years), Outstanding	3 months

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)		3 Months Ended
	May 01, 2023	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Nov. 17, 2022
Product Liability Contingency [Line Items]
Amounts remaining for services value		$ 3,648,991
Share price		$ 0.26			$ 1
Subsequent Event [Member]
Product Liability Contingency [Line Items]
Stockholders equity, reverse stock split	1-for-20 to 1-for-50
Accounts Payable [Member] | Supplier Concentration Risk [Member] | One Vendor [Member]
Product Liability Contingency [Line Items]
Concentration risk, percentage				96%
UCLA TDG [Member]
Product Liability Contingency [Line Items]
License commitment fee		$ 500,000
Proceeds from private placement percentage		2%
One Vendor [Member]
Product Liability Contingency [Line Items]
Prepaid expenses		$ 28,200
Accounts payable		2,132,791
License Agreement [Member]
Product Liability Contingency [Line Items]
Maintenance fees		10,000
License Agreement [Member] | UCLA TDG [Member]
Product Liability Contingency [Line Items]
License commitment fee		16,606	$ 22,149
Diligence fee		8,000,000
License Agreement [Member] | UCLA TDG [Member] | First Subject in Feasibility Study [Member]
Product Liability Contingency [Line Items]
License commitment fee		100,000
License Agreement [Member] | UCLA TDG [Member] | First Subject in Pivotal Study [Member]
Product Liability Contingency [Line Items]
License commitment fee		250,000
License Agreement [Member] | UCLA TDG [Member] | Pre Market Approval of Licensed Product Or Licensed Method [Member]
Product Liability Contingency [Line Items]
License commitment fee		500,000
License Agreement [Member] | UCLA TDG [Member] | First Commercial Sale of Licensed Product Or Licensed Method [Member]
Product Liability Contingency [Line Items]
License commitment fee		$ 1,000,000
License Agreement [Member] | UCLA TDG [Member] | Minimum [Member]
Product Liability Contingency [Line Items]
Percentage of commercial sale of product		10%
License Agreement [Member] | UCLA TDG [Member] | Maximum [Member]
Product Liability Contingency [Line Items]
Percentage of commercial sale of product		20%
License Agreement [Member] | Third Party [Member]
Product Liability Contingency [Line Items]
Royalty percentage reduced		0.333%
License Agreement [Member] | First Commercial Sale [Member]
Product Liability Contingency [Line Items]
Royalty expenses		$ 50,000
License Agreement [Member] | After First Commercial Sale [Member]
Product Liability Contingency [Line Items]
Royalty expenses		$ 250,000
License Agreement [Member] | Scenario 1 [Member] | UCLA TDG [Member]
Product Liability Contingency [Line Items]
Cumulative net sales description		Due upon cumulative Net Sales equaling $50,000,000 following the Triggering Sale Date - $2,000,000;
License Agreement [Member] | Scenario 2 [Member] | UCLA TDG [Member]
Product Liability Contingency [Line Items]
Cumulative net sales description		Due upon cumulative Net Sales equaling $100,000,000 following the Triggering Sale Date - $2,000,000;
License Agreement [Member] | Scenario 3 [Member] | UCLA TDG [Member]
Product Liability Contingency [Line Items]
Cumulative net sales description		Due upon cumulative Net Sales equaling $200,000,000 following the Triggering Sale Date - $4,000,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	May 01, 2023
Subsequent Event [Member]
Subsequent Event [Line Items]
Stockholders equity, reverse stock split	1-for-20 to 1-for-50